• Syndax Pharmaceuticals reported a quarterly loss of $0.98 per share, beating the Zacks Consensus Estimate.
• The company's revenue for Q1 2025 was $20.04 million, significantly exceeding expectations due to the successful launch of Revuforj®.
• Despite a negative P/E ratio, Syndax maintains a strong liquidity position with a current ratio of about 5.80.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a biopharmaceutical company focused on developing cancer therapies. The company is set to release its quarterly earnings on May 6, 2025, with Wall Street analysts estimating an earnings per share (EPS) of -$1.24 and projected revenue of $15.88 million. Syndax operates in the competitive Zacks Medical - Biomedical and Genetics industry.

In its recent Q1 2025 earnings call, Syndax reported a quarterly loss of $0.98 per share, surpassing the Zacks Consensus Estimate of a $1.04 loss. This represents a 5.77% earnings surprise. The company has exceeded consensus EPS estimates in three of the past four quarters, demonstrating a trend of outperforming expectations.

Syndax's revenue for the quarter ending March 2025 was $20.04 million, significantly exceeding the Zacks Consensus Estimate by 36.69%. This marks a substantial increase from zero revenues in the same period last year. The revenue boost is largely attributed to the successful launch of Revuforj® (revumenib), which generated $20 million in net revenue.

Despite a negative price-to-earnings (P/E) ratio of -3.50, indicating a lack of profitability, Syndax maintains a strong liquidity position with a current ratio of about 5.80. This suggests the company has sufficient current assets to cover its liabilities. The price-to-sales ratio of 26.71 reflects investor confidence in the company's future sales potential.

Syndax's financial health is further supported by $602.1 million in cash, cash equivalents, and investments, expected to sustain operations until profitability. CEO Michael Metzger attributes the quarter's success to excellent commercial execution, highlighting the company's strategic initiatives and strong market presence.